Review demonstrates mycophenolate mofetil improves outcomes in IgA nephropathy patients, suggesting individualized approaches based on intraglomerular inflammation.
Key Points
Mycophenolate mofetil is most effective in IgA nephropathy patients with early-stage intraglomerular inflammation, improving renal outcomes.
Trials in Chinese populations showed mycophenolate mofetil led to significant proteinuria reduction and delayed end-stage kidney disease progression.
Using the Oxford classification, distinct histological features can predict treatment response and guide therapeutic strategies effectively.
Identified population-based differences emphasize the need for personalized treatment decisions and further exploration in mycophenolate mofetil therapy.